Scilex Holding (SCLXW) EBT Margin (2022 - 2026)
Scilex Holding (SCLXW) recorded quarterly EBT Margin of 530.81% in Q1 2026, up 44.27% quarter-over-quarter from 952.46% in Q4 2025, and down 921.0% on a YoY basis from 64.65% in Q1 2025.
Scilex Holding (SCLXW) EBT Margin (2022 - 2026) Analysis & Trends
Scilex Holding's EBT Margin history runs 5 years deep, the most recent figure standing at 530.81% for Q1 2026.
- In Q1 2026, EBT Margin fell 921.0% year-over-year to 530.81%; the TTM figure through Mar 2026 stood at 1161.19% (down 101424.0% YoY), while the FY2025 annual figure was 1234.41%, down 110575.0% from the prior year.
- EBT Margin was 530.81% for Q1 2026 at Scilex Holding, up from 952.46% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 188.89% in Q3 2022 to a low of 2441.47% in Q3 2025.
- Historically, EBT Margin has averaged 397.14% across 5 years, with a median of 225.41% in 2022.
- The sharpest annual moves came in 2024 and 2025: EBT Margin surged 32078 bps in 2024, then tumbled 241107 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 149.71% in 2022, then retreated by 6 bps to 158.91% in 2023, then jumped by 73 bps to 43.36% in 2024, then tumbled by 2097 bps to 952.46% in 2025, then surged by 44 bps to 530.81% in 2026.
- The last three EBT Margin figures came in at 530.81% (Q1 2026), 952.46% (Q4 2025), and 2441.47% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 28.10% |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 44.70% |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 24.89% |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 6.93% |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -21.49% |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 24.18% |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 37.07% |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 135.53% |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 28.20% |
| 10 | Scilex Holding | - | - | 4.15 Mn | -530.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -530.81% |
| Dec 31, 2025 | -952.46% |
| Sep 30, 2025 | -2,441.47% |
| Jun 30, 2025 | -444.92% |
| Mar 31, 2025 | -521.60% |
| Dec 31, 2024 | -43.36% |
| Sep 30, 2024 | -30.40% |
| Jun 30, 2024 | -229.58% |
| Mar 31, 2024 | -223.97% |
| Dec 31, 2023 | -158.91% |
| Sep 30, 2023 | -351.18% |
| Jun 30, 2023 | -211.83% |
| Mar 31, 2023 | -290.54% |
| Dec 31, 2022 | -149.71% |
| Sep 30, 2022 | 188.89% |
| Jun 30, 2022 | -225.41% |
| Mar 31, 2022 | -134.17% |